[go: up one dir, main page]

WO2009063248A3 - Nouvelles formes cristallines - Google Patents

Nouvelles formes cristallines Download PDF

Info

Publication number
WO2009063248A3
WO2009063248A3 PCT/GB2008/051068 GB2008051068W WO2009063248A3 WO 2009063248 A3 WO2009063248 A3 WO 2009063248A3 GB 2008051068 W GB2008051068 W GB 2008051068W WO 2009063248 A3 WO2009063248 A3 WO 2009063248A3
Authority
WO
WIPO (PCT)
Prior art keywords
tegaserod
glutarate
polymorphic forms
novel
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/051068
Other languages
English (en)
Other versions
WO2009063248A2 (fr
Inventor
Abhay Gaitonde
Bindu Manojkumar
Sandeep Sonawane
Dattatrey Kokane
Vikas Padalkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Mylan Pharmaceuticals Pvt Ltd
Original Assignee
Generics UK Ltd
Mylan Development Centre Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd, Mylan Development Centre Pvt Ltd filed Critical Generics UK Ltd
Publication of WO2009063248A2 publication Critical patent/WO2009063248A2/fr
Publication of WO2009063248A3 publication Critical patent/WO2009063248A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne de nouvelles formes cristallines d'un sel glutarate de tégasérod et des procédés de préparation de ces nouvelles formes. L'invention concerne également des compositions pharmaceutiques contenant ces nouveaux polymorphes, et les utilisations de ces compositions dans des traitements pour des patients souffrant de troubles gastro-intestinaux.
PCT/GB2008/051068 2007-11-15 2008-11-14 Nouvelles formes cristallines Ceased WO2009063248A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2257MU2007 2007-11-15
IN2257/MUM/2007 2007-11-15

Publications (2)

Publication Number Publication Date
WO2009063248A2 WO2009063248A2 (fr) 2009-05-22
WO2009063248A3 true WO2009063248A3 (fr) 2009-07-30

Family

ID=40433743

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/051068 Ceased WO2009063248A2 (fr) 2007-11-15 2008-11-14 Nouvelles formes cristallines

Country Status (1)

Country Link
WO (1) WO2009063248A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116953A1 (fr) * 2005-05-02 2006-11-09 Zentiva, A.S. Procede de preparation de tegaserod et de sels sélectionnés dérivés de ce composé
WO2008077871A1 (fr) * 2006-12-22 2008-07-03 Novartis Ag Sels de tégasérod

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116953A1 (fr) * 2005-05-02 2006-11-09 Zentiva, A.S. Procede de preparation de tegaserod et de sels sélectionnés dérivés de ce composé
WO2008077871A1 (fr) * 2006-12-22 2008-07-03 Novartis Ag Sels de tégasérod

Also Published As

Publication number Publication date
WO2009063248A2 (fr) 2009-05-22

Similar Documents

Publication Publication Date Title
WO2008132139A3 (fr) Nouveaux dérivés hétérocycliques utiles pour le traitement des troubles du système nerveux central
WO2009067686A3 (fr) Hémi-l-malate de sunitinib, polymorphes et leur préparation, polymorphes de malate de sunitinib racémique, compositions contenant une base de sunitinib et de l'acide malique et leur préparation
WO2008152099A3 (fr) Aryl/hétarylamides en tant que modulateurs du récepteur ep2
WO2009104021A3 (fr) Nouveaux polymorphes et procédés de préparation
WO2009111700A3 (fr) Oxadiazoanthracènes pour le traitement du diabète
WO2010011772A3 (fr) Inhibiteurs de la pyrazolopyridine kinase tricyclique
WO2011069063A3 (fr) Composés multicycliques et leurs procédés d'utilisation
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
WO2010055082A3 (fr) Nouvelle forme cristalline de malate de sunitinib
WO2007138282A3 (fr) Nouveaux composés
WO2009051660A3 (fr) Composés permettant l'activation de la signalisation tgf-bêta
WO2011132051A3 (fr) Composés tricycliques en tant qu'inhibiteurs de la phosphodiestérase-10
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
WO2007052023A3 (fr) Composes
WO2008088779A3 (fr) Formes solides de 5-azacytidine et procédés de préparation de ces dernières
WO2010049449A3 (fr) Nouveaux sels de sunitinib
WO2009109501A3 (fr) Compositions pharmaceutiques oculaires
WO2010006904A3 (fr) Nouvelles formes cristallines du rabéprazole sodique
WO2011022393A3 (fr) Inhibiteurs de protéine de transfert de la phosphatidylcholine
WO2008033935A3 (fr) Dérivés de la vinorelbine
EP2084168A4 (fr) Processus pour la préparation de composés dialkyldithiophosphiniques hautement purifiés
WO2008033930A3 (fr) Dérivés de vinca
WO2010038948A3 (fr) Dérivés de pyrrole 3-carboxamide contenant de l’arylpipérazine pour le traitement de troubles dépressifs
AU2009235968A8 (en) Novel compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these
MX2010003056A (es) Polimorfos de valomaciclovir.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08848767

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08848767

Country of ref document: EP

Kind code of ref document: A2